We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
268 result(s) found, displaying 51 to 60
-
Cancellation by sponsorRequested by Janssen-Cilag Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RYBREVANT amivantamab 350 mg/7 mL concentrate for solution for infusion vial.
-
Australian public assessment report (AusPar)AusPAR for Rybrevant (amivantamab) for treatment of patients with NSCLC that has an EGFR exon 20 insertion mutation.
-
Cancellation by sponsorRequested by Janssen-Cilag Pty Ltd
-
Prescription medicine decision summaryThe medicine Tecvayli (teclistamab) has been approved by the TGA to treat multiple myeloma.
-
Prescription medicine registrationActive ingredients: T cells - Ciltacabtagene autoleucel, cryopreserved - T - CARVYKTI .
-
Prescription medicine registrationActive ingredients: teclistamab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PONVORY ponesimod 2 mg + 3 mg + 4 mg + 5 mg + 6 mg + 7 mg + 8 mg + 9 mg + 10 mg film-coated tablets (Treatment initiation pack) blister composite pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PONVORY ponesimod 20 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for INVEGA HAFYERA paliperidone (as palmitate) 1000 mg in 5 mL modified release suspension for injection pre-filled syringe.